Activation of the poly(ADP-ribose) polymerase pathway in human heart failure

Molecular Medicine

Volumn 12, Issue 7-8, 2006, Pages 143-152

  Molnár, Andrea ^a   Tóth, Attila ^a   Bagi, Zsolt ^a   Papp, Zoltán ^a   Édes, István ^a   Vaszily, Miklós ^a   Galajda, Zoltán ^a   Papp, Julius Gy ^b   Varró, András ^b   Szüts, Viktória ^b   Lacza, Zsombor ^c   Gerö, Domokos ^c   Szabó, Csaba ^c,d  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d University of Medicine and Dentistry of New Jersey   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; APOPTOSIS INDUCING FACTOR; CASPASE 9; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PEROXYNITRITE; POLY(ADENOSINE DIPHOSPHATE RIBOSE); PROTEIN; TYROSINE;

APOPTOSIS; ARTICLE; CELL DAMAGE; CELL NUCLEUS; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVATION; GENE OVEREXPRESSION; HEART DISEASE; HEART FAILURE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERVENTION STUDY; INTRACELLULAR TRANSPORT; MITOCHONDRION; NITRATION; NITROSATIVE STRESS; NORMAL HUMAN; ORGAN DONOR; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; PROTEIN RIBOSYLATION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION;

ADENOSINE DIPHOSPHATE RIBOSE; ADOLESCENT; ADULT; CARDIAC OUTPUT, LOW; CASPASE 9; ENZYME ACTIVATION; FEMALE; HEART VENTRICLES; HUMANS; MALE; MIDDLE AGED; OXIDATION-REDUCTION; POLY(ADP-RIBOSE) POLYMERASES;

EID: 33750455151     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/2006-00043.Molnar     Document Type: Article

References (44)

1. Sorescu D, Griendling KK (2002) Reactive oxygen species, mitochondria, and NAD(P)H oxidases in the development and progression of heart failure. Congest. Heart Fail. 8:132-40.
2. Ferrari R, Guardigli G, Mele D, Percoco GF, Ceconi C, Curello S (2004) Oxidative stress during myocardial ischaemia and heart failure. Curr. Pharm. Des. 10:1699-711.
3. Berry CE, Hare JM (2004) Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J. Physiol. 555:589-606.
4. Szabo C, Liaudet L, Hagl S, Szabo C (2004) Poly(ADP-ribose) polymerase activation in the reperfused myocardium. Cardiovasc. Res. 61:471-80.
5. Tyagi SC, Hayden MR (2003) Role of nitric oxide in matrix remodeling in diabetes and heart failure. Heart Fail. Rev. 8:23-8.
6. Li YY, Feldman AM (2001) Matrix metalloproteinases in the progression of heart failure: potential therapeutic implications. Drugs 61:1239-52.
7. Xiao CY, Chen M, Zsengeller Z, Li H, Kiss L, Kollai M, Szabo C (2005) Poly(ADP-ribose) polymerase promotes cardiac remodeling, contractile failure, and translocation of apoptosis-inducing factor in a murine experimental model of aortic banding and heart failure. J. Pharmacol. Exp. Ther. 312:891-8.
8. Szabo C, O'Connor M, Salzman AL (1997) Endogenously produced peroxynitrite induces the oxidation of mitochondrial and nuclear proteins in immunostimulated macrophages. FEBS Lett. 409:147-50.
9. Pacher P, Obrosova IG, Mabley JG, Szabo C (2005) Role of nitrosative stress and peroxynitrite in the pathogenesis of diabetic complications: emerging new therapeutical strategies. Curr. Med. Chem. 12:267-75.
10. Borbely A et al. (2005) Peroxynitrite-induced alpha-actinin nitration and contractile alterations in isolated human myocardial cells. Cardiovasc. Res. 67:225-33.
11. Soldani C, Scovassi AI (2002) Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update. Apoptosis 7:321-8.
12. Virag L, Szabo C (2002) The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol. Rev. 54:375-429.
13. Hengartner MO (2000) The biochemistry of apoptosis. Nature 407:770-6.
14. Nakamura K et al. (2002) Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation 105:2867-71.
15. Mallat Z, Philip I, Lebret M, Chatel D, Maclouf J, Tedgui A (1998) Elevated levels of 8-isoprostaglandin F2alpha in pericardial fluid of patients with heart failure: a potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure. Circulation 97:1536-9.
16. Ide T et al. (2000) Direct evidence for increased hydroxyl radicals originating from superoxide in the failing myocardium. Circ. Res. 86:152-7.
17. Giordano FJ (2005) Oxygen, oxidative stress, hypoxia, and heart failure. J. Clin. Invest. 115:500-8.
18. Massion PB, Feron O, Dessy C, Balligand JL (2003) Nitric oxide and cardiac function: ten years after, and continuing. Circ. Res. 93:388-98.
19. Szabo C (2003) Multiple pathways of peroxynitrite cytotoxicity. Toxicol. Lett. 140-141:105-12.
20. Fukuchi M, Hussain SN, Giaid A (1998) Heterogeneous expression and activity of endothelial and inducible nitric oxide synthases in end-stage human heart failure: their relation to lesion site and beta-adrenergic receptor therapy. Circulation 98:132-9.
21. Mungrue IN et al. (2002) Cardiomyocyte overexpression of iNOS in mice results in peroxynitrite generation, heart block, and sudden death. J. Clin. Invest. 109:735-43.
22. Gealekman O, Abassi Z, Rubinstein I, Winaver J, Binah O (2002) Role of myocardial inducible nitric oxide synthase in contractile dysfunction and beta-adrenergic hyporesponsiveness in rats with experimental volume-overload heart failure. Circulation 105:236-43.
23. Damy T et al. (2004) Increased neuronal nitric oxide synthase-derived NO production in the failing human heart. Lancet 363:1365-7.
24. Ferdinandy P, Danial H, Ambrus I, Rothery RA, Schulz R (2000) Peroxynitrite is a major contributor to cytokine-induced myocardial contractile failure. Circ. Res. 87:241-7.
25. Szabo C et al. (2002) Part I: pathogenetic role of peroxynitrite in the development of diabetes and diabetic vascular complications: studies with FP15, a novel potent peroxynitrite decomposition catalyst. Mol. Med. 8:571-80.
26. Pacher P et al. (2003) Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. Circulation 107:896-904.
27. Frustaci A et al. (2000) Myocardial cell death in human diabetes. Circ. Res. 87:1123-32.
28. Hunt MJ, Aru GM, Hayden MR, Moore CK, Hoit BD, Tyagi SC (2002) Induction of oxidative stress and disintegrin metalloproteinase in human heart end-stage failure. Am. J. Physiol. Lung Cell Mol. Physiol. 283:L239-45.
29. Pacher P, Liaudet L, Mabley J, Komjati K, Szabo C (2002) Pharmacologic inhibition of poly(adenosine diphosphate-ribose) polymerase may represent a novel therapeutic approach in chronic heart failure. J. Am. Coll. Cardiol. 40:1006-16.
30. Pacher P, Liaudet L, Soriano FG, Mabley JG, Szabo E, Szabo C (2002) The role of poly(ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes. Diabetes 51:51421.
31. Pillai JB, Russell HM, Raman J, Jeevanandam V, Gupta MP (2005) Increased expression of poly(ADP-ribose) polymerase-1 contributes to caspase-independent myocyte cell death during heart failure. Am. J. Physiol Heart Circ. Physiol. 288:H486-96.
32. Di Napoli P et al. (2003) Left ventricular wall stress as a direct correlate of cardiomyocyte apoptosis in patients with severe dilated cardiomyopathy. Am. Heart J. 146:1105-11.
33. Kumar D, Jugdutt BI (2003) Apoptosis and oxidants in the heart. J. Lab. Clin. Med. 142:288-97.
34. Hughes SE (2003) Detection of apoptosis using in situ markers for DNA strand breaks in the failing human heart. Fact or epiphenomenon? J. Pathol. 201:181-6.
35. Ducharme A et al. (2000) Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J. Clin. Invest. 106:55-62.
36. Kwan JA et al. (2004) Matrix metalloproteinase-2 (MMP-2) is present in the nucleus of cardiac myocytes and is capable of cleaving poly (ADP-ribose) polymerase (PARP) in vitro. FASEB J. 18:690-2.
37. Szabo C et al. (2002) Poly(ADP-ribose) polymerase is activated in subjects at risk of developing type 2 diabetes and is associated with impaired vascular reactivity. Circulation 106:2680-6.
38. Jagtap P, Szabo C (2005) Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat. Rev. Drug Discov. 4:421-40.
39. Fischer UM et al. (2003) Cardioplegic arrest induces apoptosis signal-pathway in myocardial endothelial cells and cardiac myocytes. Eur. J. Cardiothorac. Surg. 23:984-90.
40. Okada H et al. (2005) Myocardial apoptotic index based on in situ DNA nick end-labeling of endomyocardial biopsies does not predict prognosis of dilated cardiomyopathy. Chest 128:1060-2.
41. Zorc M, Vraspir-Porenta O, Zorc-Pleskovic R, Radovanovic N, Petrovic D (2003) Apoptosis of myocytes and proliferation markers as prognostic factors in end-stage dilated cardiomyopathy. Cardiovasc. Pathol. 12:36-9.
42. Zorc M et al. (2001) Myocytes' apoptosis and proliferation in endomyocardial biopsy as prognostic factors in terminal heart failure. Pflugers Arch. 442:R163-4.
43. Koda M et al. (2003) Myocytes positive for in situ markers for DNA breaks in human hearts which are hypertrophic, but neither failed nor dilated: a manifestation of cardiac hypertrophy rather than failure. J. Pathol. 199:229-36.
44. Bartunek J, Vanderheyden M, Knaapen MW, Tack W, Kockx MM, Goethals M (2002) Deoxyribonucleic acid damage/repair proteins are elevated in the failing human myocardium due to idiopathic dilated cardiomyopathy. J. Am. Coll. Cardiol. 40:1097-103.